Foghorn Swings to $58.2M Q3 Net Income, Extends Cash Runway to 2H 2029
FHTX is trading near its 52-week low of $1.79 (4.5% above the low).
Summary
Foghorn reported Q3 2026 net income of $58.2M, almost entirely from a $74.1M catch-up adjustment after dropping the Lilly-partnered programs, and said $156.2M in cash funds operations into the second half of 2029. The pipeline is now wholly owned but early — first-in-human for the IBD program is targeted by end of 2027.
Key Events · Earnings and Guidance · FHTX
-
Q3 Swing to Net Income on Catch-Up Adjustment
Net income was $58.2M versus a $15.8M net loss a year earlier, driven by collaboration revenue of $83.5M that included a $74.1M cumulative catch-up adjustment tied to the decision not to advance FHD-909 and the SMARCA2 selective degrader.
-
Cash Runway Extended to Second Half 2029
Cash, cash equivalents and marketable securities totaled $156.2M at September 30, 2026, funding operations into the second half of 2029 versus the mid-2027 runway in the prior baseline.
-
Restructuring Costs Booked in the Quarter
The quarter included $2.3M of restructuring costs, reflecting the 40% workforce reduction disclosed on October 1, 2026 alongside the Lilly program discontinuation.
-
Wholly Owned Pipeline With 2027 Milestones
The IBD oral small molecule begins dose-range finding in Q4 2026 with first-in-human targeted by end of 2027; the selective EP300 degrader has an IND targeted in 2027 focused on multiple myeloma and DLBCL.
Analysis · FHTX · Life Sciences
The headline profit is an accounting event, not an operating one: $83.5M of collaboration revenue includes a $74.1M cumulative catch-up adjustment triggered by formally abandoning the Lilly-partnered FHD-909 and SMARCA2 programs. What actually changes the thesis is the balance sheet. With $156.2M of cash and runway now into the second half of 2029 — roughly two years beyond the mid-2027 runway in the prior baseline — the company has bought time to advance wholly owned programs. Those programs remain early: the IBD small molecule targets first-in-human by end of 2027 and the EP300 degrader targets an IND in 2027, so there is no near-term clinical readout to reprice the stock. With shares near the 52-week low of $1.79, the market is valuing the platform at a steep discount to cash plus deferred revenue; today's filing does not add a catalyst, it removes a financing overhang.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FHTX was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $111.1M. The 52-week trading range was $1.79 to $7.61. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.